Objective Outcomes Michael Klompas MD, MPH, FRCPC, FIDSA Harvard Medical School, Harvard Pilgrim Health Care Institute, and Brigham and Women’s Hospital,

Slides:



Advertisements
Similar presentations
The Eradication of VAP in Scotland Martin Hughes Nov 2010.
Advertisements

Prevention of Ventilator Associated Pneumonia
Eliminate Ventilator-Associated Pneumonia. What Is a Ventilator? A machine that supports breathing for those that have lost the ability to breathe Short.
Beyond VAP: Identifying areas for improvement to prevent ventilator-associated conditions Michael Klompas MD, MPH, FRCPC, FIDSA Harvard Medical School,
Reducing Ventilator Associated Pneumonia in Adults Intensive Care Units Confidential: Quality Improvement Material.
© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 CUSP for VAP: EVAP NHSN VAE Surveillance Definition Review Call in.
Implementing a Ventilator-Associated Pneumonia Bundle in an Academic Emergency Department L.A. DeLuca, L.R. Stoneking, K. Grall, A. Tran, J. Rosell, A.
1 Acute Cough Definitions of Lower Respiratory Tract Infections (LRTI), ranging in severity: Acute bronchitis - an acute respiratory tract infection in.
Sahar Elkaradawy Assistant Professor in Anaesthesia and Intensive Care Unite.
OUR LADY OF LOURDES MEMORIAL HOSPITAL Binghamton, New York Reducing Complications From Ventilators in ICU: Ventilator Associated Pneumonia (VAP)
Ventilator Associated Pneumonia Best Practice Amy Shay, MS, CCRN, CNS Amy Shay, MS, CCRN, CNS.
Sean Berenholtz, MD MHS FCCM September 20, 2011 at 2ET/1 CT/12 MT/11 PT Ventilator Associated Pneumonia Prevention CLABSI Supplemental Call Series.
Ventilator-Associated Pneumonia. Introduction Definition 48 hours after intubation mechanically ventilated No clinical evidence of pneumonia prior to.
Journal Club. Background to the paper Pneumonia is THE MOST COMMON nosocomial infection in ICU patients 12 to 18 cases per 1000 ventilator days Oropharyngeal.
Current Challenges in the ICU Prof Craig Williams Institute of Healthcare Associated Infection UWS.
ICU 101 a.k.a. “Papers You Should Know” Ashley Henderson, MD May 4, 2010.
Safer Healthcare Now! Ventilator Acquired Pneumonia Presented by Amanda Thompson, Safer Healthcare Now Facilitator April 12, 2007.
Preventing VAP - evidence for a care bundle. VAP Incidence ~ % ventilated patients 7-15 / 1000 ventilator days Atributable mortality of 0-50% Atributable.
Reports: Daily Process, VAE, NHSN
Welcome !!! Please join us via phone for the audio portion of the webinar, you will be connected by the operator when the meeting begins. Conference Line.
Protective Lung Strategy Mazen Kherallah, MD, FCCP
1 Telligen Quality Innovation Network- Quality Improvement Organization Ventilator Associated Events –VAE June 26, 2015 This material was prepared by Telligen,
) Benchmarking Critical Care Outcomes: Using data to drive effectiveness and efficiency Thomas L. Higgins MD MBA Vice Chair for Clinical.
Ventilator-Associated Events A Patient Safety Opportunity Michael Klompas MD, MPH, FRCPC, FIDSA, FSHEA Harvard Medical School, Harvard Pilgrim Health Care.
GENERAL TEMPLATE FOR A 48”X36” POSTER Name(s) of Author(s) 1 ; Name(s) of Author(s) 2 ; Name(s) of Author(s) 3 1. Name of Institution; 2. Name on Institution;
VAP Intervention Information
The TEXAS Wake Up and Breathe Quality Improvement Initiative: Data Collection Activities Terri Conner, PhD Nybeck Analytics Project Manager Texas Wake.
Epidemiology of Mechanical Ventilation Antonio Anzueto MD Professor of Medicine University of Texas Health Science Center, San Antonio, Texas.
Clinical Uses and Ramifications of VAE Data
CUSP 4 MVP – VAP Improving Care for Mechanically Ventilated Patients Strategies for Collecting and Entering Early Mobility ARMSTRONG INSTITUTE FOR PATIENT.
Ventilator-Associated Events A Patient Safety Opportunity
Ventilator-associated events: a patient safety opportunity Michael Klompas MD, MPH, FRCPC, FIDSA Harvard Medical School, Harvard Pilgrim Health Care Institute,
The Cardiac Surgery Translational Study (“CSTS”) The Quality And Safety Research Group Ventilator Associated Pneumonia Prevention Sean Berenholtz, MD MHS.
CHEST. 2007;131(4): Methylprednisolone Infusion in Early Severe ARDS - Results of a Randomized Controlled Trial.
CUSP 4 MVP – VAP Improving Care for Mechanically Ventilated Patients Infection Prevention 2 VAE Surveillance Training: Infectious Ventilator-Associated.
© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 CUSP for VAP: EVAP NHSN VAE Surveillance Definition Review Presented.
Part I BACKGROUND VENTILATOR ASSOCIATED PNEUMONIA.
© The Johns Hopkins University and The Johns Hopkins Health System Corporation, 2011 VAP Prevention Bundle: Evidence Review for Oral Care and Subglottic.
ความหมาย As Pneumonia in patient who have been on mechanical ventilation for greater than 48 hrs.
CUSP 4 MVP – VAP Improving Care for Mechanically Ventilated Patients Data 3: Introduction to Objective Outcome Measures ARMSTRONG INSTITUTE FOR PATIENT.
A PRACTICAL GUIDE FAYE DEAL, RN CIC LISA BROWN, MT(ASCP) CIC VAE.
TEMPLATE DESIGN © Noninvasive mechanical ventilation in the weaning of patients with respiratory failure due to COPD.
RBC transfusions in critically ill patients TMR Journal Club March 1, 2007 Maggie Constantine.
CUSP 4 MVP – VAP Content Webinar Data Feedback and Team Presentation on All Sedation Data From Daily Care Processes Wednesday, February 11, 2015, 2:00-3:00.
Spontaneous Awakening and Breathing Trials Brad Winters MD, PhD March 14, 2013.
The CDC Prevention Epicenters’ Wake Up and Breathe Collaborative
นพ. ธรรมศักดิ์ ทวิช ศรี หน่วยเวชบำบัด วิกฤต ฝ่ายวิสัญญีวิทยา รพ. จุฬาลงกรณ์
Raghavan Murugan, MD, MS, FRCP Associate Professor of Critical Care Medicine, and Clinical & Translational Science Core Faculty, Center for Critical Care.
CUSP 4 MVP – VAP Improving Care for Mechanically Ventilated Patients Infection Prevention: VAE Surveillance Training: An Overview ARMSTRONG INSTITUTE FOR.
Mini BAL v/s Bronchoscopic BAL PROF. PRADYUT WAGHRAY MD (CHEST), DTCD, FCCP (USA),D.SC(PULM. MEDICINE) HEAD OF DEPT. OF PULMONARY MEDICINE S.V.S MEDICAL.
CUSP 4 MVP – VAP Improving Care for Mechanically Ventilated Patients Data Feedback: SubG ETT, Head of Bed Elevation and Delirium Assessment Utilization.
Strategies to Prevent Ventilator-Associated Pneumonia in Acute Care Hospitals 2014 Update Dr Neda Alijani.
Context, Interpretation, Next Steps Linda Greene MS, RN Michael Klompas MD, MPH November 12, 2014 CUSP for Mechanically Ventilated Patients Interim Results.
The Problem ARDS - mortality % Etiology - unknown Therapy - largely supportive »mechanical ventilation Lung injury How do you ventilate the ARDS.
PREVENTION Kaplan University Capstone NU499 VENTILATOR – ASSOCIATED PNEUMONIA VAP PREVENTION at Sparks Regional Medical Center.
MICROBIOLOGICAL EPIDEMIOLOGY OF RESPIRATORY SPECIMENS IN ICU PATIENTS Dr Farooq Cheema, Dr Waseem Tariq, Dr Raja Ishtiaq, Dr Tabassum Qureshi, Dr Vincent.
Acute Respiratory Distress Syndrome
E A B C D Reducing Delirium in the ICU Patient: The ABCDE Bundle
Ventilator Associated Pneumonia. Ventilator-associated pneumonia (VAP) is a form of hospital-associated pneumonia (HAP) which develops in mechanically.
Using Subglottic Endotracheal Tubes in Preventing Ventilator Assisted Pneumonia By: Nicole Durrance, Adriana Gomez, Esther Gonzalez, Marzette Solis BACKGROUND.
VAE/VAP: Definitions, Algorithms and Best Practices
Poster template by ResearchPosters.co.za Ventilator Associated Pneumonia rates in Intensive Care. Lori J. Delaney Assistant Professor: University of Canberra,
Depart. Of Pulmonology and Critical Care Medicine R4 백승숙.
Community Acquired Pneumonia. Definitions Community acquired pneumonia (CAP) – Infection of the lung parenchyma in a person who is not hospitalized or.
Weaning From Mechanical Ventilation
Ventilator-Associated Pneumonia
Monitoring Patients on Mechanical Ventilation: A New Paradigm Terri Conner, Ph.D. Nybeck Analytics May 2012.
Update in Critical Care Medicine Ann Intern Med 2007;147:
Subglottic Suctioning
Surveillance of Post-operative pneumonia
Presentation transcript:

Objective Outcomes Michael Klompas MD, MPH, FRCPC, FIDSA Harvard Medical School, Harvard Pilgrim Health Care Institute, and Brigham and Women’s Hospital, Boston, USA CUSP for Mechanically Ventilated Patients October 7, 2014 What are they? Why do they matter?

Disclosures Grant funding from the US Centers for Disease Control and Prevention Honoraria from Premier Healthcare Alliance for lectures on VAP surveillance

Ventilator-associated pneumonia Affects ~5-10% of ventilated patients Increases ICU length of stay by ~4-7 days Increases hospital length of stay by ~14 days Crude mortality rate 30-50% Attributable mortality 8-12% Adds ~$10-50,000 to cost of hospital stay CMS 1533-P, 2007 Safdar et al, Crit Care Med 2005; 33:2184 Tejerina et al, J Crit Care 2006; 21:56 Muscedere et al, J Crit Care 2008;23:5-10 Eber et al, Arch Intern Med 2010;170: Nguile-Makao et al, Intensive Care Med 2010;36:781-9 Beyersmann et al, Infect Control Hosp Epidemiol 2006;27:493

Diagnostic Criteria for VAP High Temp Low Temp High WBC Low WBC Low P:F Ratio Increased vent settings Purulent secretions Gram stain neutrophils New Antibiotic Start Infiltrate CDC Old Definition ✓✓✓✓✓✓✓ CDC New Definition ✓✓✓✓✓✓✓ HELICS Criteria ✓✓✓✓✓ ACCP Criteria ✓✓✓✓✓ Clinical Pulmonary Infection Score ✓✓✓✓✓✓✓ Johanson’s Criteria ✓✓✓✓ Ego et al. Chest 2014;ePub ahead of print

Impact of Diagnostic Criteria on VAP Prevalence Prospective surveillance, 1824 patients, Tertiary Med-Surg Unit, Belgium Ego et al. Chest 2014;ePub ahead of print

All VAP Signs Subjective, Non-Specific, or Both The core clinical signs associated with VAP: Radiographic opacities Fever Abnormal white blood cell count Impaired oxygenation Increased pulmonary secretions

Interobserver agreement in VAP surveillance 7 IP 1 (11 VAPs) IP 2 (20 VAPs) IP 3 (15 VAPs) Klompas, AJIC 2010:38:237 Kappa = ventilated patients with respiratory deterioration

6 Case Vignettes Presented to 43 Surveyors Crit Care Med 2014;42:497

Accuracy of clinical diagnosis of VAP Relative to 253 autopsies 80% 100% Sensitivity / Positive Predictive Value 60% 40% 20% 0% Positive Predictive Value Tejerina et al., J Critical Care 2010;25:62 Sensitivity Loose definition: Infiltrate and 2 of temp / wbc / purulence Strict definition: Infiltrate and 3 of temp / wbc / purulence

Accuracy of quantitative BAL cultures Relative to histology 80% 100% Sensitivity / Positive Predictive Value 60% 40% 20% 0% Positive Predictive Value Kirtland, Chest 1997;112:445 Fabregas, Thorax 1999;54:867 Chastre, Am Rev Respir Dis 1984;130:924 Torres, Am J Resp Crit Care Med 1994;149:324 Marquette, Am J Resp Crit Care Med 1995;151:1878 Papazian, Am J Resp Crit Care Med 1995;152:1982 Sensitivity

Implications for prevention

from doctorrw.blogspot.com

The VAP Prevention Paradox VAP Rates Vent LOS ICU LOS Hospital LOS Death Regular oral care with chlorhexidine Silver-coated endotracheal tubes Head-of-bed elevation Crit Care 2009;13:315

VAP diagnosis is subjective VAP diagnosis is non-specific Many VAP studies under-powered Reasons for the Prevention Paradox The case of chlorhexidine The case of silver-coated ETTs The case of head of bed elevation

VAP diagnosis is subjective VAP diagnosis is non-specific Many VAP studies under-powered Reasons for the Prevention Paradox The case of chlorhexidine The case of silver-coated ETTs The case of head of bed elevation

Oral CHG in Non-Cardiac Surgery Patients Open Label Studies: RR 0.61 ( ) Double-Blind Studies: RR 0.88 ( ) JAMA Internal Med 2014;174:751

Routine Oral Care with Chlorhexidine Impact on mean duration of mechanical ventilation: NONE Impact on ICU length-of-stay NONE Impact on mortality POSSIBLE INCREASE!!! RR 1.13 (0.99 to 1.28) JAMA Internal Med 2014;174:751

VAP diagnosis is subjective VAP diagnosis is non-specific Many VAP studies under-powered Reasons for the Prevention Paradox The case of chlorhexidine The case of silver-coated ETTs The case of head of bed elevation

Silver-Coated Endotracheal Tubes VAP Rates and Outcomes VAP Incidence VAPs per 100 Patients Conventional ETTsSilver coated ETTs Lengths of Stay (days) Vent days ICU days Hospital days JAMA 2008;300:805

Silver-coated endotracheal tubes Microbiological Outcomes VAP Counts Included: yeast, normal flora, coag-neg Staph, & Enterococcus

VAP diagnosis is subjective VAP diagnosis is non-specific Many VAP studies under-powered Reasons for the Prevention Paradox The case of chlorhexidine The case of silver-coated ETTs The case of head of bed elevation

Reducing the risk of ventilator-acquired pneumonia through head of bed elevation Nursing Crit Care 2007;12:287 N=221 N=86 N=30 78%  in VAP, P=.04 71%  in VAP, P>.10 46%  in VAP, P>.10

Semi-recumbent position and ICU Days Drakulovic, Lancet 1999 (difference in means) van Nieuwenhoven, CCM 2006 (difference in medians) Keeley, Nursing Crit Care 2007 (not reported) Difference in ICU Length of Stay Favors Semi-Recumbent Position Favors Supine Position ??? All studies

Critical Care Medicine 2013;41:

Ventilator -associated conditions (VAC) Rise in daily minimum PEEP ≥3cm or FiO2 ≥20 sustained ≥2 days after ≥2 days of stable or improving daily minimum PEEP or FiO2

Impact of VAEs on length-of-stay Controlled for time to VAE, age, sex, unit, comorbidities, severity of illness. All comparisons are to patients without VAE (control). Control VAC *** IVAC *** Possible VAP *** Probable VAP *** Control VAC *** IVAC *** Possible VAP *** Probable VAP *** Days Infect Control Hosp Epidemiol 2014;5:

Impact of VAEs on mortality Odds Ratio or Hazard Ratio USA – 3 centers PLoS ONE 2011;6:e18062 USA – 8 centers Crit Care Med 2012;40:3154 Canada – 11 centers Chest 2013;144:1453 Netherlands – 2 centers Am J Resp Crit Care Med 2014;189:947 USA – 2 centers Crit Care Med 2014;ePub USA – 1 center Infect Control Hosp Epidemiol 2014;5:502 VAEVAP

Canadian Critical Care Trials Group ABATE Study Enhanced care for vented patients, 11 ICUs, 1330 patients Muscedere et al. Chest 2013;144:

Conservative Fluid Management 304 patients randomized to daily BNP levels versus usual care Patients randomized to daily BNP levels More diuretics, negative fluid balance Less time to extubation 50% fewer VAEs P=.02 Dessap et al. Chest 2014; ePub ahead of print

The VAP Prevention Paradox VAP Rates Vent LOS ICU LOS Hospital LOS DeathVAEs Regular oral care with chlorhexidine ? Silver-coated endotracheal tubes ? Head-of-bed elevation ? Crit Care 2009;13:315

The Upshot VAP rates are unreliable outcomes VAE rates likely reliable but still very new. Unclear how best practices will impact them. If we want to know whether a prevention measure really works or not, we have to look at objective outcomes such as: duration of mechanical ventilation ICU length-of-stay hospital length-of-stay mortality

Minimize sedation Greater sedation associated with longer ventilator and ICU stays. Increases risk for pneumonia and other infections. RCT data from Denmark showing that vented patients can be adequately managed with NO sedation Spontaneous awakening trials associated with less overall sedative use and earlier extubation al/midazolam-1mg-5ml/ NEJM 1996;335:1864-9NEJM 2000;342: Lancet 2008;371: Lancet 2010;375:475-80

Paired daily sedative interruptions and spontaneous breathing trials Spontaneous breathing trials associated with earlier extubation Patients are more likely to pass spontaneous breathing trials if they’re awake for the trial RCT data showing that pairing SATs with SBTs speeds extubation by ~3 days and shortens ICU and hospital LOS by ~4 days compared to SBTs alone Lancet 2008;371: NEJM 1996;335: Wake Up and Breathe

Early mobility – Wake Up & Walk! Early mobilization assocaited with less time to extubation and shorter ICU stays May also help prevent atelectasis & delirium As with improved sedative management and weaning protocols, less time on vent means less time at risk for VAEs CareCom0610Fig2.jpg Lord et al., Crit Care Med 2013;41:717 Schweickert et al., Lancet 2009;373:1874 Needham et al., Arch Phys Med Rehabil 2010;91:536

Low tidal volume ventilation Higher tidal volumes associated with acute lung injury Randomized controlled trial data showing that lower tidal volumes protect against acute lung injury in patients without ARDS and lower mortality rates in patients with ARDS Determann, Critical care 2010;14(1):R1 ARDSnet, NEJM 2000;342: volume-is-better-when-ventilating-patients-after-cardiac-surgery/

Summary VAP diagnosis is subjective and non-specific Inconsistent association between VAP and patient outcomes Many interventions purportedly lower VAP rates but no impact on patient outcomes: “the VAP Prevention Paradox”. Makes VAP an unreliable outcome VAEs more objective and consistently predict adverse outcomes… but the definitions are still very new, very little data so far on how prevention strategies impact VAE rates Implication: need to look at objective outcomes if we want to be sure that CUSP 4 MVP is helping our patients

Michael Klompas Thank you!

Am J Resp Crit Care Med 2014;8:947 Chest 2014;ePub ahead of print